New ALS treatment, AMX0035, lacks evidence of benefit, FDA panel findings

With a vote of 6-4, the group of independent advisers to the agency narrowly concluded that results from another clinical trial are needed to assess whether the treatment, called AMX0035, can help patients.

Leave a Reply

Your email address will not be published. Required fields are marked *